Sandusky, OH -- July 24, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today announced the company has scheduled to close the acquisition of Puration, Inc.’s (USOTC: PURA) cannabis spinoff next week, on Tuesday, July 28, 2020.  PAOG has further scheduled to close the acquisition of Kali-Extracts’s (USOTC:KALY) NCM Biotech subsidiary next week, on Thursday, July 30, 2020.

NCM Biotech has patented cannabis extraction operation which is focused on medical research and the development of treatments derived from its patented cannabis extraction process. See a recent research report on CBD extracts derived from NCM Biotech's patented extraction process: Journal of Cannabis Research.

PURA’s cannabis cultivation operation is thriving, has revenue, and has recently purchased and relocated to a new property from its former leased property. Texas lawmakers have recently implemented hemp friendly farming regulations and in so doing, universities within the State of Texas have initiated hemp farming research programs. PURA's cannabis cultivation spinoff has initiated a number of joint research applications with Texas universities.

PURA had previously spun-off its cannabis cultivation operation to Nouveau (USOTC: NOUV) and is now unwinding that deal to move forward with PAOG.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

 

Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Nouveau Life Pharmaceuti... (PK).
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Nouveau Life Pharmaceuti... (PK).